Pathogenic Role of Advanced Glycation End-Products (Ages): An Overview

Held P. , Port F. , Webb R. , Wolfe R.A. , Bloembergen W. , Turenne M. Excerpts from United States Renal Data System 1996 Annual Data Report Am J Kidney Dis. 1996; 28(Suppl 2): S1–165.

Agodoa L. , Held P.J. , Port F.K. United States Renal Data System, USRDS 1995 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Am J Kidney Dis. 1995; 26: (Suppl 2).

Vanholder R. , Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: A Review. J Am Soc Nephrol. 1993; 3: 1541–54.

Vlassara H. Serum advanced glycosylation end-products: A new class of uremic toxins? Blood Purif. 1994; 12: 54–9.

Ritz E. , Deppisch R. , Nawroth P. Toxicity of uraemia Does it come of AGE? Nephrol Dial Transplant. 1994; 9: 1–2.

Sell D.R. , Monnier V.M. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest. 1990; 85: 380–4.

Makita Z. , Radoff S. , Rayfield E.J. , Yang Z. , Skolnik E. , Delaney V. Advanced glycosylation end-products in patients with diabetic nephropathy. N Engl J Med. 1991; 325: 836–42.

Monnier V.M. , Sell D.R. , Miyata S. , Nagaraj R.H. , Odetti P. , Lapolla A. Advanced Maillard reaction products as markers for tissue damage in diabetes and uraemia: Relevance to diabetic nephropathy. Acta Diabetol. 1992; 29: 130–5.

Makita Z. , Bucala R. , Rayfield E.J. , Friedman E.A. , Kaufman A.M. , Korbet S.M. Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet. 1994; 343: 1519–22.

Friedlander M. , Wu Y. , Schulak J. , Monnier V. , Hricik D. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with endstage renal disease. Am J Kidney Dis. 1995; 25: 445–51.

Miyata T. , Ueda Y. , Shinzato T. , Iida Y. , Tanaka S. , Kurakawa K. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol. 1996; 7: 1198–206.

Wolff S. , Jiang Z. , Hunt J. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med. 1991; 10: 339–52.

Thornalley P.J. Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress. Baillieres Clin Endocrinol Metab. 1996; 3: 146–66.

Miyata T. , Wada Y. , Cal Z. , Iida Y. , Horie K. , Yasuda Y. Implication of an increased oxidative stress in the formation of advanced glycation end-products in patients with end stage renal failure. Kidney Int. 1997; 51: 1170–81.

Friedlander M. , Wu Y. , Randle C. , Baumgardner G. , DeOreo P. , Monnier V. eds. Increased formation of pentosidine and Nε-(carboxymethyl)lysine in end stage renal disease: Role of dialysis clearance. In: O'Brien J. , Nursten H.E. , Crabbe M.J.C. , Ames J.M. , eds. The Maillard Reaction in Foods and Medicine. London: Royal Society of Chemistry; 1998: 339–44.

Fu M. , Requena J. , Jenkins A. , Lyons T. , Baynes J. , Thorpe S. The advanced glycation end product, Nε-(carboxy - methyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem. 1996; 271: 9982–6.

Anderson M. , Hazen S. , Hsu F. , Heinecke J. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy -amino acids into glycoaldehyde, 2-hydroxypropanal and acrolein: A mechanism for the generation of highly reactive α-hydroxy and α,β-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest. 1997; 99: 397–403.

Baynes J. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991; 40: 405–12.

Ahmed M. , Thorpe S. , Baynes J. Identification of Nε-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem. 1986; 261: 4889–94.

Dyer D.G. , Blackledge J.A. , Thorpe S.R. , Baynes J.W. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem. 1991; 266: 11654–60.

Grandhee S. , Monnier V. Mechanism offormation of the Maillard protein cross-link pentosidine. J Biol Chem. 1991; 266: 11649–53.

Jontofsohn R. , Trivisas G. , Katz N. , Kluthe R. Amino acid content of erythrocytes and plasma in uremia. Am J Clin Nutr. 1978; 31: 1956–60.

Halliwell B. , Gutteridge J. Role of free radicals and catalytic metal ions in human diseases: An overview. Methods Enzymol. 1990; 186: 1–85.

Niwa T. , Takeda N. , Miyazaki T. , Yoshizumi H. , Tatematsu A. , Maeda K. Elevated serum levels of 3-deoxy glucosone, a potent protein-cross-linking intermediate of the Maillard reaction, in uremic patients. Nephron. 1995; 69: 438–43.

Friedlander M. , Wu Y. , Elgawish A. , Monnier V. Early and advanced glycosylation end-products: Kinetics of formation and clearance in peritoneal dialysis. J Clin Invest. 1996; 97: 728–35.

Roselaar S. , Nazhat N. , Winyard P. , Jones P. , Cunningham J. , Blake D. Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int. 1995; 48: 199–206.

Witko-Sarsat V. , Friedlander M. , Capeillere Blandin C. , Nguyen-Khoa T. , Nguyen A. , Zingraff J. Advanced oxidative protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996; 49: 1304–13.

Itabe H. , Yamamoto H. , Imanaka T. , Shinamura K. , Uchiyama H. , Kimura J. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res. 1996; 37: 45–53.

Maggi E. , Bellazzi R. , Falaschi F. , Frattoni A. , Perani G. , Finardi G. Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int. 1994; 45: 876–83.

Ponka A. , Kuhlback B. Serum ascorbic acid in patients undergoing chronic hemodialysis. Acta Med Scand. 1983; 213: 305–7.

Loughrey C. , Young I. , Lightbody J. , McMaster D. , McNamee P. , Trimbel E. Oxidative stress in hemodialysis. Q J Med. 1994; 87: 679–83.

Cohen J. , Viljoen M. , Clifford D. , DeOliveria A. , Veriava Y. , Milne F. Plasma vitamin E levels in chronically hemolyzing group of dialysis patients. Clin Nephrol. 1986; 25: 42–7.

Ueda Y. , Miyata T. , Hashimoto T. , Yamada H. , Izuhara Y. , Sakai H. Implication of altered redox regulation by antioxidant enzymes in the increased plasma pentosidine, an advanced glycation end product, in uremia. Biochem Biophys Res Commun. 1998; 245: 785–90.

Miyata T. , Maeda K. , Kurokawa K. , van Ypersele de Strihou C. Oxidation conspires with glycation to generate noxious advanced glycation end-products in renal failure. Nephrol Dial Transplant. 1997; 12: 255–8.

Bucala R. , Makita Z. , Vega G. , Grundy S. , Koschinsky T. , Cerami A. Modification of LDL by advanced glycosylation end-products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA. 1994; 91: 9441–5.

Steinberg D. Role of oxidized LDL and antioxidants in atherosclerosis. Adv Exp Med Bioi. 1995; 369: 39–48.

Schmidt A. , Hori O. , Brett J. , Yan S.D. , Wautier J-L , Stern D. Cellular receptors for advanced glycation end-products: Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb. 1994; 14: 1521–8.

Yan S. , Schmidt A. , Anderson G. , Zhang J. , Brett J. , Zou Y. Enhanced cellular oxidant stress by the interaction of advanced glycation end-products with their receptors/binding proteins. J Biol Chem. 1994; 269: 9889–97.

Wautier J.L. , Wautier M.P. , Schmidt A.M. , Anderson G.M. , Hori O. , Zoukourian C. Advanced glycation endproducts (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface associated AGEs and diabetic complications. Proc Natl Acad Sci U S A. 1994; 91: 7742–6.

Imani F. , Horii Y. , Suthanthiran M. , Skolnik E. , Makita Z. , Sharma V. Advanced glycosylation end product specific receptors on human and rat T-lymphocytes mediate synthesis ofinterferon-ϒ: Role in tissue remodeling. J Exp Med. 1993; 178: 2165–72.

Araki N. , Higashi T. , Mori T. , Shibayama R. , Kawabe Y. , Kodama T. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end-products of the Maillard reaction. Eur J Biochem. 1995; 230: 408–15.

Horiuchi S. , Higashi T. , Ikeda K. , Saishoji T. , Jinnouchi Y. , Sano H. Advanced glycation end-products and their recognition by macrophage and macrophage derived cells. Diabetes. 1996; 45: S73–6.

Shaw S. , Crabbe J. Nonspecific binding of advanced glycosylation end-products to macrophages outweighs specific receptor mediated interactions. Biochem J. 1994; 309: 121–9.

Westwood M. , McLellan A. , Thornalley P. Receptor mediated endocytic uptake of methylglyoxal-modified serum albumin. J Biol Chem. 1994; 269: 32293–8.

Schmidt A. , Yan S. , Brett J. , Mora R. , Nowygrod R. , Stern D. Regulation of human mononuclear phagocyte migration by cell surface binding proteins for AGEs. J Clin Invest. 1993; 91: 2155–68.

Doi T. , Vlassara H. , Kirstein M. , Yamada Y. , Striker G. , Striker L. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end-products is mediated via platelet-derived growth factor. Proc Natl Acad Sci U S A. 1992; 89: 2873–7.

Pugliese G. , Pricci F. , Romeo G. , Pugliese F. , Mene P. , Giannini S. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end-products via a receptor-mediated mechanism. Diabetes. 1997; 46: 1881–7.

Schmidt A. , Mora R. , Rong C. , Yan S. , Brett J. , Ramakrishnan R. The endothelial cell binding site for advanced glycation end-products consists of a complex: An integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem. 1994; 269: 9882–8.

Greten J. , Kreis I. , Wiesel K. , Stier E. , Schmidt A. , Stem D. Receptors for advanced glycation end-products (AGE) -Expression by endothelial cells in nondiabetic uremic patients. Nephrol Dial Transplant. 1996; 11: 786–90.

Hogan M. , Cerami A. , Bucala R. Advanced glycosylation end-products block the antiproliferative effect of nitric oxide. J Clin Invest. 1992; 90: 1110–15.

Miyata T. , Notoya K. , Yoshida K. , Horie K. , Maeda K. , Kurokawa K. Advanced glycation end-products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol. 1997; 8: 260–70.

Brett J. , Schmidt A. , Yan S. , Zou Y. , Weidman E. , Pinsky D. Survey of the distribution of a newly characterized receptor for advanced glycation end-products in tissues. Am J Pathol. 1993; 143: 1699–712.

Miyata T. , Hori O. , Zhang J. , Yan S. , Ferran L. , Iida Y. The receptor for advanced glycation end-products (RAGE) is a central mediator of the interaction of AGEβ2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloid. J Clin Invest. 1996; 98: 1088–94.

Miyata T. , Inagi R. , Iida Y. , Sato M. , Yamada N. , Oda O. Involvement of β2-microglobulin modified with advanced glycation end-products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest. 1994; 93: 521–8.

Vlassara H. , Brownlee M. , Manogue K. , Pasagian A. , Dinarello C. Cachectin/TNF and IL-l induced by glucose modified proteins: Role in normal tissue remodeling. Science. 1988; 240: 1546–8.

Vlassara H. , Fuh H. , Donnelly T. , Cybulsky M. Advanced glycation end-products promote adhesion molecule (VCAM -l, ICAM -l) expression and atheroma formation in normal rabbits. Mol Med. 1995; 4: 447–56.

Vlassara H. , Fuh H. , Makita Z. , Krungkrai S. , Cerami A. , Bucala R. Exogenous advanced glycosylation end-products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. Proc Natl Acad Sci U SA. 1992; 89: 12043–7.

Schmidt A. , Hori O. , Chen J. , Li J. , Crandell J. , Zhang J. Advanced glycation end-products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-l) in cultured human endothelial cells and in mice: A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest. 1995; 96: 1395–403.

Libby P. , Hansson G. Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions. Lab Invest. 1991; 64: 5–15.

Nguyen A. , Lethais C. , Zingraff J. , Herbelin A. , Naret C. , Descamps-Latscha B. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro with microamounts of whole blood. Kidney Int. 1985; 28: 158–67.